Features
Automated LVEF calculation from standard DICOM echo studies
AI detection of cardiac amyloidosis from A4C and PLAX views
FDA 510(k) clearance for Precision LVEF and Precision Cardiac Amyloid
Prospective randomized controlled trial published in Nature
DICOM-native post-processing (no new hardware or scanners)
PACS and Epic EHR integration
CPT Category III code 0932T for reimbursement (effective Jan 1, 2025)
Breakthrough Device designation and FDA TAP enrollment for cardiac amyloid
Zero marginal clinician burden per study
Multi-indication pipeline (LVEF, amyloid, cirrhosis, reporting, valve disease)
Developed in collaboration with Alexion (AstraZeneca Rare Disease)
Clinically validated in peer-reviewed journals
Precision Cirrhosis for opportunistic liver disease detection
Precision Reporting with EchoPrime foundation model
Multi-valve algorithms (mitral, tricuspid, aortic in development)
AI-driven clinical and molecular data analysis
Tempus xT DNA/RNA sequencing panel (648 genes)
Tempus LENS cloud-based analytics tool
Real-world evidence generation
De-identified patient record aggregation (7M+ records)
Genomic alteration detection
Treatment outcome prediction
Multimodal data integration (genomic, clinical, imaging)
Physician decision support
Tempus PRO AI-assisted notetaking for neurologists
ECG-AI for cardiovascular patient identification
Tempus Pixel radiology therapy response evaluation
Pharmaceutical research data access
